14 / 64
CARMENA: Phase III Study of
Sunitinib
vs
Nephrectomy + Sunitinib
Sunitinib
Nephrectomy
50 mg/day
(Schedule 4/2)
Metastatic
R
A
N
D
O
Sunitinib
50 mg/day
N=576
clear-cell
RCC
M
I
S
A
T
I
(Schedule 4/2)
NCT00930033
O
N
Primary objective
:
Is sunitinib alone non-inferior to nephrectomy plus
sunitinib in terms of overall survival?
PI: Arnaud Mejean (CCAFU, HEGP, Paris, France)